EMENDOBIO
LIVE

Serial Number

90798006

Owner

EmendoBio Inc.

Attorney

LAUREN GREGORY LEIPOLD

Filing Date

Jun 28, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EMENDOBIO Trademark

Serial Number: 90798006

EMENDOBIO is a trademark filed by EmendoBio Inc. on June 28, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

EmendoBio Inc. (3 trademarks)

4th Floor
New York, NY 10069

Entity Type: 03

Trademark Details

Filing Date

June 28, 2021

Registration Date

Not Registered

Published for Opposition

December 27, 2022

Goods & Services

Enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research purposes; nucleases and nuclease panels derived from biotechnological processes for use in scientific and research purposes; assays and reagents for use in genetic research; nucleases and nuclease panels for use in genetic research

Enzyme preparations for medical purposes; enzymes for medical purposes; nucleases and nuclease panels for medical purposes; reagents for use in medical genetic testing; preparations for detecting genetic predispositions for medical purposes; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the prevention of diseases or decisions caused by genetic predispositions; pharmaceutical preparations for editing of faulty genes; chemical preparations for pharmaceutical or medical purposes, namely, for editing of faulty genes; anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; ocular pharmaceuticals; pharmaceutical preparations and substances for the treatment of genetic blood disorders

Testing, research, or development of pharmaceutical preparations for gene therapy; testing, research, selection, optimization or development of nucleases for gene targeting, gene editing, or gene therapy; DNA analysis services for scientific research purposes; genetic testing for scientific research purposes; scientific research in the field of genetics, gene editing and genetic engineering; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific research consulting in the field of genetics; scientific research consulting in the field of gene editing; scientific research consulting in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; scientific research in the field of selection and optimization of nucleases for gene editing and pharmaceutical development; pharmaceutical research services in the field of genetics and gene therapy, excluding production technologies; pharmaceutical research and development in the field of genetics and gene therapy, excluding production technologies; pharmaceutical products development in the field of genetics and gene therapy; pharmaceutical product evaluation in the field of genetics and gene therapy; pharmaceutical drug development services in the field of genetics and gene therapy, excluding production technologies; development of pharmaceutical preparations and medicines in the field of genetics and gene therapy; technical research in the field of pharmaceutical studies in the field of genetics and gene therapy, excluding production technologies; research and development in the pharmaceutical and biotechnology fields of genetics and gene therapy, excluding production technologies; testing of pharmaceuticals in the field of genetics and gene therapy; laboratory research services relating to pharmaceuticals in the field of genetics and gene therapy; conducting early evaluations in the field of new pharmaceuticals in the field of genetics and gene therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the field of genetics and gene therapy; medical research services in the field of genetics and gene therapy; medical research services in the field of genetic blood disorders; medical research services in the field of genetic ocular disorders; scientific research for medical purposes in the field of gene editing and genetic disorders; scientific research for medical purposes in the field of nuclease and nuclease panel discovery and optimization for the development of gene-targeting pharmaceuticals

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 9, 2026 EXRA
SOU EXTENSION 2 GRANTED
Apr 8, 2026 EX2G
SOU EXTENSION 2 FILED
Apr 8, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 8, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 5, 2025 EXRA
SOU EXTENSION 1 GRANTED
Nov 5, 2025 EX1G
SOU EXTENSION 1 FILED
Nov 4, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 4, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 6, 2025 NOAM
TTAB RELEASE CASE TO TRADEMARKS
Mar 24, 2025 TMBN
OPPOSITION TERMINATED NO. 999999
Mar 24, 2025 OP.T
OPPOSITION DISMISSED NO. 999999
Mar 24, 2025 OP.D
ASSIGNED TO EXAMINER
Mar 10, 2025 DOCK
OPPOSITION INSTITUTED NO. 999999
Jun 26, 2023 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 24, 2023 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 22, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 3, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 3, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 3, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 3, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 3, 2022 CNRT
ASSIGNED TO EXAMINER
Mar 18, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 10, 2021 NWOS
NEW APPLICATION ENTERED
Jul 1, 2021 NWAP